In exploratory analyses, we then examined relationships between changes in CSF markers of inflammation, immune function and vascular integrity and clinical/AD biomarker outcomes, reasoning that correlated changes with insulin treatment might reflect underlying mechanisms related to its beneficial effects, whereas correlated changes in the placebo group might reflect the natural progression of AD. This evidence concerns the gene INS and Alzheimer disease.